10-Q: UroGen Pharma Q3 2025: Zusduri Launch, R&D Pipeline & Lease Extension

UroGen Pharma reports Q3 2025 results, highlighting the commercial launch of Zusduri, progress in its RTGel pipeline, and a significant lease extension for its Princeton headquarters, alongside increased operating losses.

Summary

• Net loss for the third quarter of 2025 increased to $(33.3) million, compared to $(23.7) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(127.1) million, an increase from $(89.4) million for the nine months ended September 30, 2024.
• Revenue for Q3 2025 was $27.5 million, up from $25.2 million in Q3 2024, driven by higher Jelmyto sales and the commercial launch of Zusduri.
• Revenue for the nine months ended September 30, 2025, was $72.0 million, compared to $65.8 million for the same period in 2024.
• Zusduri, approved by the FDA on June 12, 2025, for recurrent low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC), commenced promotion in late June 2025 and generated $1.8 million in sales.
• The company discontinued the development of UGN-301 in November 2025, providing notice to terminate the license agreement with Agenus.
• The lease for the Princeton, New Jersey headquarters was extended through April 30, 2031, with base rent commencing February 1, 2026, at $0 for the first three months, then increasing annually.
• Cash and cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025, down from $276.1 million at December 31, 2024.
• Patent infringement litigation against Teva Pharmaceuticals, Inc. regarding Jelmyto patents is ongoing, with a bench trial scheduled for October 2026.

Sentiment

Score: 4

Explanation: While the company achieved a significant FDA approval and launched Zusduri, and has other pipeline progress, the substantial increase in net losses and operating losses, coupled with a significant reduction in cash and marketable securities, indicates a challenging financial period. The discontinuation of UGN-301 also reflects a setback in one program. The explicit mention of the need for future capital raises underscores ongoing financial pressures despite commercial progress.

Positives

• FDA approval of Zusduri on June 12, 2025, as the first and only FDA-approved non-surgical treatment for recurrent low-grade intermediate risk NMIBC.
• Successful commercial launch of Zusduri in late June 2025, achieving broad patient access with over 95% of covered lives (approximately 296 million eligible patients) through Commercial, Medicare, and Medicaid insurance programs.
• Jelmyto sales increased to $25.7 million in Q3 2025 from $25.2 million in Q3 2024, contributing to overall revenue growth.
• UGN-103 Phase 3 UTOPIA trial completed patient enrollment with 99 patients globally, and the FDA has agreed to an NDA submission based on this data.
• Initiation of a Phase 3 trial for UGN-104 in low-grade UTUC in June 2025.
• Acquisition of ICVB-1042 (now UGN-501), a next-generation investigational oncolytic virus, with a Phase 1 clinical study planned for 2026.
• Jelmyto was granted a New Technology Ambulatory Payment Classification (APC) effective October 1, 2023, and Zusduri was assigned a unique, permanent J-code (J9282) by CMS, effective January 1, 2026.
• The company believes it has sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements.
• Recognized an income tax benefit of approximately $1.1 million in Q3 2025 due to the One Big Beautiful Bill Act (OBBBA) reinstating the ability to immediately expense domestic research and development expenditures.

Negatives

• Net loss for Q3 2025 increased to $(33.3) million from $(23.7) million in Q3 2024, representing a 40.5% increase.
• Net loss for the nine months ended September 30, 2025, increased to $(127.1) million from $(89.4) million in 2024, a 42.2% increase.
• Operating loss for Q3 2025 increased to $(27.4) million from $(17.5) million in Q3 2024, a 56.1% increase.
• Operating loss for the nine months ended September 30, 2025, increased to $(105.7) million from $(69.1) million in 2024, a 53.0% increase.
• Cash and cash equivalents and marketable securities significantly decreased from $276.1 million at December 31, 2024, to $127.4 million at September 30, 2025.
• Net cash used in operating activities increased to $(124.1) million for the nine months ended September 30, 2025, from $(83.1) million for the same period in 2024.
• Research and development expenses increased by $2.6 million in Q3 2025 and $10.5 million for the nine months ended September 30, 2025.
• Selling and marketing expenses increased by $5.9 million in Q3 2025 and $19.9 million for the nine months ended September 30, 2025.
• General and administrative expenses increased by $2.7 million in Q3 2025 and $9.6 million for the nine months ended September 30, 2025.
• Discontinuation of UGN-301 development in November 2025, as its clinical profile did not meet internal benchmarks for advancement to Phase 2.
• The company elected not to draw down the fourth tranche of $75.0 million from the Pharmakon loan, which was available until August 29, 2025.
• Interest and other income, net, decreased due to lower cash and investment balances and a lower interest rate trend in 2025.

Risks

• The company may require additional financing to fund its operations and achieve its goals, and a failure to obtain this capital could force delays or termination of product development or commercialization efforts.
• Highly dependent on the successful commercialization of its approved products, Jelmyto and Zusduri, which face risks related to physician adoption, market acceptance, and competition.
• Limited experience in marketing and distributing products, posing challenges in successfully commercializing Jelmyto, Zusduri, and any future approved product candidates.
• Market opportunities for Jelmyto, Zusduri, and product candidates may be smaller than anticipated or limited to specific patient populations, impacting commercial success.
• Jelmyto, Zusduri, and product candidates, if approved, will face significant competition from existing technologies and other pharmaceutical companies, including potential generic competition for Jelmyto from Teva Pharmaceuticals.
• Clinical drug development is a lengthy, expensive, and uncertain process, and results of earlier studies and trials may not be predictive of future trial results.
• Reliance on third-party subcontractors and single-source suppliers for raw materials, compounds, and components necessary for product manufacturing and clinical trials, increasing risks of supply disruption and increased costs.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, financial condition, results of operations, and prospects.
• Product liability lawsuits could result in substantial liabilities and may require the company to limit commercialization of its products.
• Failure to attract and retain senior management and key personnel could hinder successful product development, clinical trials, and commercialization.
• Information technology systems or data, or those of third parties, could be compromised, leading to regulatory investigations, litigation, fines, and business disruptions.
• The company's employees, independent contractors, clinical investigators, CROs, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading.
• The business involves the use of hazardous materials, and compliance with environmental laws and regulations can be expensive and restrict business operations.
• Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively affect earnings.
• Health pandemics, epidemics, or other public health emergencies could adversely affect the business.
• Geopolitical, economic, and military instability in Israel, where certain operations and key vendors are located, could adversely affect results.
• Provisions of Israeli law and the company's articles of association may delay, prevent, or impede a merger or acquisition.
• Difficulty enforcing a judgment of a U.S. court against the company and its officers and directors in Israel or the United States.
• Shareholder rights and responsibilities are governed by Israeli law, which differs from U.S. law.
• If the FDA concludes that the requirements for relevant product candidates are not as expected, the approval pathway could be significantly longer, costlier, and riskier.
• Current and future legislation affecting the healthcare industry, including healthcare reform (e.g., ACA, IRA, OBBBA), may impact the business and increase limitations on reimbursement, rebates, and other payments.
• Approved products will be subject to ongoing regulatory obligations and continued regulatory review, potentially resulting in significant additional expenses, limited or withdrawn regulatory approval, and penalties for non-compliance.
• Difficulty in profitably selling products if coverage and reimbursement are limited by government authorities and/or third-party payor policies.
• May not obtain Orphan Drug Designation or exclusivity for future product candidates, and competitors could obtain exclusivity for similar products.
• The market price of ordinary shares has been and may continue to be subject to fluctuation, potentially leading to investment losses.
• Future sales of ordinary shares could reduce the market price.
• Future equity offerings could result in future dilution and cause the price of ordinary shares to decline.
• If classified as a passive foreign investment company (PFIC), U.S. shareholders may suffer adverse tax consequences.
• Changes to tax laws could have a material adverse effect and reduce net returns to shareholders.
• Tax authorities may disagree with tax positions and conclusions, resulting in unanticipated costs or taxes.
• Ability to use U.S. net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be limited.
• Actions of activist shareholders could negatively affect the business and impact the trading value of securities.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations.
• Unstable market, economic, and geopolitical conditions (e.g., Israel-Hamas war, Russia-Ukraine war) may have serious adverse consequences on the business, financial condition, and share price.
• The business could be negatively impacted by environmental, social, and corporate governance matters or related reporting.

Future Outlook

The company expects to continue incurring losses and negative net cash flows from operating activities as it pursues the commercial launch of Zusduri, continued commercialization of Jelmyto, and further research and development activities. It believes its current cash and marketable securities are sufficient to fund operations beyond one year from the financial statement issuance date. However, if cash inflows from product sales are insufficient, additional capital may be required, or operating expenditures may need to be reduced. The company anticipates submitting an NDA for UGN-103 in the second half of 2026, with potential FDA approval in 2027, and plans to initiate a Phase 1 clinical study of UGN-501 in 2026.

Management Comments

• "We expect to incur losses and have negative net cash flows from operating activities as we execute our strategy, including the commercial launch of Zusduri, the continued commercialization of Jelmyto, and engaging in further research and development activities."
• "Based on our cash and cash equivalents and marketable securities as of September 30, 2025, together with managements cash flow projections, we believe we have sufficient cash and cash equivalents to fund our operations beyond one year from the issuance of our condensed consolidated financial statements."
• "If we are unable to generate sufficient cash inflows from Jelmyto and Zusduri product sales, we may need to raise additional capital in the future or reduce operating expenditures."
• "While the Phase 1 clinical study of UGN-301 confirmed proof of concept for our proprietary RTGel technology as a viable platform for local delivery of complex immunotherapies, UGN-301s overall clinical profile did not meet our internal benchmarks for advancement to Phase 2."

Industry Context

UroGen Pharma operates in the highly competitive biotechnology and uro-oncology sector, specializing in innovative non-surgical treatments for urothelial and specialty cancers using its proprietary RTGel technology. The FDA approval and commercial launch of Zusduri for recurrent low-grade intermediate risk NMIBC represents a significant advancement, positioning it as a potential new standard of care against traditional surgical procedures like TURBT. The company's pipeline, including UGN-103, UGN-104, and the newly acquired UGN-501, indicates a continued focus on expanding its non-surgical treatment options. However, the discontinuation of the UGN-301 program underscores the inherent risks and high attrition rates in drug development. The company faces competition from both established pharmaceutical giants and emerging biotech firms, as well as the threat of generic competition for its approved products, as evidenced by the ongoing litigation with Teva Pharmaceuticals.

Comparison to Industry Standards

• Zusduri is the first and only FDA-approved non-surgical treatment for recurrent low-grade intermediate risk NMIBC, offering an alternative to the existing standard of care, transurethral resection of bladder tumor (TURBT).
• The company's RTGel technology significantly extends drug dwell time in the urinary tract (e.g., 4-6 hours for mitomycin with RTGel vs. ~5 minutes for standard aqueous mitomycin), potentially improving efficacy compared to conventional formulations.
• RTGel allows for higher doses of active drugs; for instance, up to 8 mg of mitomycin can be formulated with 1 mL of RTGel, compared to 0.5 mg in 1 mL of water.
• The high recurrence rates of low-grade intermediate risk NMIBC (approximately 68% of patients have two or more recurrences) highlight the unmet need that Zusduri aims to address, potentially reducing the need for repeated surgical procedures.
• Patients undergoing multiple TURBT procedures face increased risks (e.g., 14% greater risk of death for 2-4 procedures vs. one), which Zusduri's non-surgical approach aims to mitigate.
• The 77.8% three-month Complete Response (CR) rate for UGN-103 in the UTOPIA trial is consistent with results from the ENVISION clinical trial for Zusduri, suggesting a comparable efficacy profile for the next-generation formulation.
• Jelmyto is the first drug therapy of its kind for low-grade UTUC, providing a non-surgical alternative to endoscopic resection(s) and radical nephroureterectomy.
• The company faces competition from various pharmaceutical companies in urology and uro-oncology, including AADi LLC, Aura Biosciences, Inc., Biocancell Ltd., Bristol Myers Squibb, CG Oncology Inc., enGene Holdings, Ferring Pharmaceuticals (Adstiladrin approved for high-risk BCG-unresponsive NMIBC in 2023), FKD Therapies Oy, GSK, ImmunityBio, ImPact Biotech Ltd., Johnson & Johnson (Inlexzo approved for high-grade BCG-unresponsive NMIBC in September 2025), LIPAC Oncology, Merck Sharp & Dohme Corp, Pfizer, Prokarium, Protara Therapeutics, Relmada Therapeutics, Roche, Samyang Biopharma, SURGE Therapeutics, Trigone Pharma, Tyra Biosciences, Viralytics Limited and Vyriad.

Corporate Governance

Legal Proceedings

• Patent infringement lawsuit filed on April 2, 2024, against Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., alleging infringement of U.S. Patent Numbers 9,040,074, 9,950,069, and 12,268,745 related to Jelmyto.
• Teva submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to manufacture, use, or sell a generic version of Jelmyto.
• The parties stipulated that upon final FDA approval of Teva's ANDA, the commercial manufacture, use, sale, or importation of that product would infringe certain asserted patent claims, narrowing the scope of the action to the validity of those patent claims.
• A bench trial for this matter is scheduled for October 2026.
• If the company is unsuccessful in securing the requested court relief, Jelmyto may be subject to immediate competition from an FDA-approved generic product after regulatory exclusivity expires in April 2027.

Related Party Transactions

• In February 2025, the company acquired assets from IconOVir Bio, Inc. Entities affiliated with Arie Belldegrun, M.D., the Chair of the Board of Directors, held promissory notes of IconOVir and may receive approximately 28.3% of the $4.0 million purchase price paid to IconOVir.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and increased losses, but may benefit from the successful commercialization of Zusduri and pipeline progression. The outcome of the Teva patent litigation could significantly impact Jelmyto's market exclusivity and future revenue.
• Employees may experience opportunities from the expansion of the sales force and commercial team for Zusduri, but the discontinuation of the UGN-301 program could affect some R&D personnel.
• Customers (healthcare providers and patients) gain a new non-surgical treatment option (Zusduri) for NMIBC, potentially improving quality of life by reducing the need for surgery. Jelmyto continues to be available for UTUC.
• Suppliers, particularly single-source providers of key components like mitomycin API and hydrogel, face continued reliance, which could pose supply chain risks if disruptions occur.
• Creditors, including Pharmakon and RTW Investments, are impacted by the company's financial performance and strategic decisions, such as the election not to draw down an additional loan tranche and the extension of the Pharmakon loan repayment period. RTW payments are tied to product sales performance.

Next Steps

• Complete the ongoing ENVISION trial to further characterize the clinical benefit of Zusduri for recurrent low-grade intermediate risk NMIBC.
• Provide FDA updates on Duration of Response (DOR) for all patients with ongoing Complete Responses (CRs) from the ENVISION trial until recurrence, progression, death, loss to follow-up, or 63 months after first instillation.
• Submit a New Drug Application (NDA) for UGN-103 in the second half of 2026, with potential FDA approval in 2027.
• Initiate a Phase 1 clinical study of UGN-501 as a locally administered agent in patients with recurrent NMIBC in 2026.
• Continue to assess the extent to which deferred tax assets may be realized in the future.
• Participate in a bench trial for the patent infringement litigation against Teva Pharmaceuticals, Inc. scheduled for October 2026.
• Commence repayment period for the Pharmakon loan in the second quarter of 2027.

Key Dates

Recommendation

The company has achieved a significant milestone with the FDA approval and commercial launch of Zusduri, which addresses a large market with a novel non-surgical approach. This, along with progress in other pipeline candidates (UGN-103, UGN-104, UGN-501), provides a strong growth narrative. However, the substantial increase in net losses and operating expenses, coupled with a significant reduction in cash and marketable securities, indicates ongoing financial challenges and a clear need for future capital. The discontinuation of UGN-301 is a setback, and the ongoing patent litigation for Jelmyto introduces uncertainty regarding future revenue streams. Given the mixed financial performance and the balance of promising product development against significant operational costs and funding needs, a 'hold' recommendation is appropriate for investors to monitor the commercial ramp-up of Zusduri and the outcomes of the patent litigation before making further investment decisions.

Keywords

UroGen Pharma, URGN, biotechnology, urothelial cancer, Jelmyto, Zusduri, RTGel, NMIBC, UTUC, mitomycin, oncology, clinical trials, FDA approval, lease extension, Q3 2025 earnings, pharmaceuticals, drug development, patent litigation, capital raise, financial results